AGC to manufacture adjuvant for Novavax COVID-19 vaccine

By The Science Advisory Board staff writers

June 3, 2020 -- AGC Biologics announced it is partnering with Novavax for large-scale good manufacturing practices production of critical components for Novavax's coronavirus vaccine candidate, NVX-CoV2373.

AGC will manufacture Matrix-M, the adjuvant component of the vaccine candidate that helps enhance the immune response and stimulate high levels of neutralizing antibodies. The vaccine candidate is a prefusion protein made using Novavax's proprietary nanoparticle technology.

AGC plans to optimize process development for rapid scale-up of Matrix-M to increase Novavax's capacity to deliver doses of the vaccine this year. Phase I clinical trial results for NVX-CoV2373 are expected in July.

Copyright © 2020
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here